Could John Hancock’s Longevity Series Reveal Deeper Health Ambitions for Manulife (TSX:MFC)?

• In late October 2025, John Hancock, a subsidiary of Manulife Financial, launched a six-part documentary series called "Longer. Healthier. Better." exploring advances in longevity, aging, and wellness through insights from leading experts in medicine and science.
• This initiative expands John Hancock's wellness engagement platform and highlights the company's commitment to providing innovative tools that support healthier, longer lives for its insurance customers.
• We'll explore how John Hancock's focus on longevity innovation supports Manulife's broader investment case in health-focused insurance solutions.

This technology could replace computers: discover 27 stocks that are working to make quantum computing a reality.

Manulife Financial Investment Narrative Recap

To stand behind Manulife Financial as a shareholder, you need to believe in the company's ability to drive long-term value through innovation in health-driven insurance, disciplined capital management, and new growth across Asia and the U.S. The launch of John Hancock's longevity-focused docuseries is a brand and engagement move that may not materially influence the most pressing short-term catalyst, sustained new business expansion or address the key risk of margin pressure from Hong Kong’s eMPF transition beginning 2026.

However, the July launch of the Manulife Real Asset Pooled Fund directly targets a critical catalyst: capturing retirement savings opportunities as populations age, particularly in Canada. By broadening its retirement solutions, Manulife positions itself to benefit from growing demand for diversified, health and longevity-linked asset management services, although its performance will also hinge on maintaining strong margins in the face of regulatory changes in key Asian markets.

Yet, despite these developments, the growing regulatory-driven margin compression in Hong Kong’s MPF business is a risk investors should not overlook, especially as...

Read the full narrative on Manulife Financial (it's free!)

Manulife Financial is projected to reach CA$55.3 billion in revenue and CA$7.7 billion in earnings by 2028. This outlook assumes a 21.0% annual revenue growth rate and a CA$2.3 billion increase in earnings from the current CA$5.4 billion level.

Uncover how Manulife Financial's forecasts yield a CA$49.13 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members have posted seven fair value estimates for Manulife, ranging from CA$49.13 to CA$106.17, showing a wide spread of opinions. While many expect robust new business growth in Asia and the U.S., both risks and opportunities remain in focus, explore what others are forecasting and why their views differ.

Explore 7 other fair value estimates on Manulife Financial - why the stock might be worth over 2x more than the current price!

Build Your Own Manulife Financial Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Manulife Financial research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Manulife Financial research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Manulife Financial's overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• Find companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com